Steven Love Sells Shares of OmniAb, Inc.

On June 17, 2026, insider Steven Love sold 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). The transaction did not appear to be part of a pre-planned trading program.

What Changed in Steven Love's OmniAb Position

Steven Love's recent transaction involved the sale of 20,000 shares. This change reflects an adjustment in his holdings, although the specific impact on his overall position isn't detailed in the available data.

Other Institutional Activity in OmniAb

Several institutional investors have recently modified their holdings in OmniAb. BlackRock, Inc. increased its stake by 41,900 shares, bringing its total to 8,106,881 shares valued at about $12.7 million. Meanwhile, Geode Capital Management, LLC added 202,887 shares, ending with 2,925,579 shares worth approximately $4.6 million. On the other hand, Cadian Capital Management, LP reduced its position by 277,825 shares, leaving 4,157,129 shares valued at around $6.5 million. Vanguard Capital Management LLC made a significant move by acquiring 3,993,652 shares, now holding shares worth $6.3 million.

OmniAb, Inc. Stock Down 47.7%

Shares of OmniAb, Inc. (NasdaqGM: OABI) traded near $2.34. The company has a market cap of approximately $339.2 million and a forward P/E ratio that is not meaningful because it isn't currently profitable. The stock's beta is 1.146, indicating moderate volatility. Over the past year, the stock has ranged from a low of $1.30 to a high of $2.79. It has a 50-day moving average of $1.97 and a 200-day moving average of $1.80. OmniAb maintains a strong liquidity position with a current ratio of 4.80 and a quick ratio of 4.55, though its debt-to-equity ratio stands at 7.49.

Recent Earnings

OmniAb reported revenue of $28.94 million, with a modest growth rate of 2.47%. However, the company is currently unprofitable, with a net margin of -187.6% and a return on equity of -20.25%. Investors may look forward to the next earnings report, expected on August 6, 2026.

Insider Buying and Selling at OmniAb, Inc.

On the same day as Steven Love's transaction, other insiders were active in OmniAb's stock. Jennifer Cochran bought 40,000 shares and sold 20,000 shares, while Carolyn Bertozzi acquired 60,000 shares and sold 20,000 shares. John Higgins also purchased 20,000 shares. None of these transactions were part of planned trading programs.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on OmniAb. RBC Capital maintained its buy rating with a $3.00 price target on August 7, 2025. Benchmark reiterated its buy rating with a $6.00 target on May 12, 2025. HC Wainwright & Co. also reiterated a buy rating, setting an $11.00 target on March 19, 2025. The consensus among six analysts is a buy rating, with an average price target of $7.33.

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company based in Emeryville, California. It focuses on licensing discovery research technology to pharmaceutical and biotech companies, as well as academic institutions. OmniAb's technology platform helps in the discovery of therapeutics by creating diverse antibody repertoires. The company's platforms include OmniRat, OmniChicken, and OmniMouse, which are genetically modified to generate human sequence antibodies. OmniAb was founded in 2012 and is led by CEO Matthew W. Foehr.

Bottom Line

Insider transactions, such as Steven Love's sale of shares, are closely watched by investors for potential signals about a company's future. OmniAb's stock is currently trading in a volatile range, reflecting its ongoing financial challenges. As always, 13F filings and insider activity are backward-looking and may not represent current positions or future strategies.